Core Viewpoint - The company has entered into a collaboration agreement with Aohong Pharmaceutical for exclusive commercialization rights of a product in the field of HR+ and HER2– breast cancer treatment, enhancing its pipeline and revenue potential [1] Group 1: Collaboration Agreement - The collaboration agreement was signed on December 3, 2025, following a memorandum of understanding established on August 7, 2025 [1] - Aohong Pharmaceutical grants the company exclusive rights for the commercialization of the product within a specified region and field [1] - The memorandum of understanding has been replaced by the collaboration agreement and will automatically terminate on December 3, 2025 [1] Group 2: Product Details - The licensed product, citric acid voraselis capsule, is a CDK4/6 inhibitor approved for the treatment of HR+ and HER2– breast cancer [1] - The product aligns with the company's commercialization strategy in the breast cancer sector and has commercial synergy with existing breast cancer pipeline products [1] - Introducing this licensed product will enrich the company's pipeline and leverage its existing breast cancer commercialization team and resources to enhance future revenue scale [1]
复宏汉霖就枸橼酸伏维西利胶囊与奥鸿药业订立合作协议